Ipca Laboratories shares declined 2% to trade at ₹1,701.00 on Monday, continuing to be a closely watched stock within the Nifty Midcap 150 index. The stock has delivered a year-to-date return of -12.92% on the Nifty Midcap 150 index, reflecting ongoing investor interest despite recent volatility. According to latest reports, the company maintains a market capitalization of ₹44,792 crore and continues to be a significant constituent of the midcap segment.
For the quarter-ending March 2026, Ipca Laboratories reported consolidated revenue of ₹2,388.48 crore, representing a 6.31% growth from ₹2,246.69 crore in the same quarter of the previous year. Net profit for the same period stood at ₹309.40 crore, showing a significant increase of approximately 370.47% from ₹65.78 crore in March 2025, though it experienced a 14.99% decline from the December 2025 peak of ₹364.05 crore. Earnings Per Share (EPS) for the March 2026 quarter improved to ₹13.31 compared to ₹12.09 in the December 2025 quarter and ₹2.67 in March 2025.
The company's annual consolidated financial results show consistent growth over the last five years. Revenue increased by 65.46% from ₹5,829.79 crore in March 2022 to ₹9,646.33 crore in March 2026. Net profit demonstrated strong recovery, growing from ₹910.95 crore in March 2022 to ₹1,191.37 crore in March 2026, representing an increase of approximately 30.78% after a dip in 2023. EPS also grew by 33.58% year-on-year in 2026, reaching ₹46.94, while the company's Return on Equity (ROE) improved to 14.15% in March 2026 from 10.61% in March 2025.
The company has announced a final dividend of ₹6.00 per share (600%) for fiscal year 2026, representing a 50% increase from the ₹4.00 per share dividend announced in 2025. Ipca Laboratories has scheduled a board meeting for August 13, 2026, to consider and approve its standalone and consolidated financial results for the first quarter ended June 30, 2026. The company's cash flow from operating activities remained strong at ₹1,141 crore in March 2026, though it decreased by approximately 13.62% from ₹1,321 crore in March 2025. The company maintains a healthy Debt to Equity ratio of 0.09 as of March 2026, with key financial ratios including a P/E ratio of 34.11x and P/B ratio of 5.04x.
